School of Public Health, University of California, Berkeley, CA, USA.
Program in Comparative Biochemistry, University of California, Berkeley, CA, USA.
Methods Mol Biol. 2024;2822:419-429. doi: 10.1007/978-1-0716-3918-4_26.
Ribozymes engineered from the RNase P catalytic RNA (M1 RNA) represent promising gene-targeting agents for clinical applications. We describe in this report an in vitro amplification and selection procedure for generating active RNase P ribozyme variants with improved catalytic efficiency. Using the amplification and selection procedure, we have previously generated ribozyme variants that were highly active in cleaving a herpes simplex virus 1-encoded mRNA in vitro and inhibiting its expression in virally infected human cells. In this chapter, we use an overlapping region of the mRNAs for the IE1 and IE2 proteins of human cytomegalovirus (HCMV) as a target substrate. We provide detailed protocols and include methods for establishing the procedure for the amplification and selection of active mRNA-cleaving RNase P ribozymes. The in vitro amplification and selection system represents an excellent approach for engineering highly active RNase P ribozymes that can be used in both basic research and clinical applications.
核酶 P 催化 RNA(M1 RNA)工程化的核酶代表了用于临床应用的很有前途的基因靶向试剂。本报告介绍了一种体外扩增和筛选程序,用于生成具有提高催化效率的活性核酶 P 核酶变体。使用扩增和筛选程序,我们之前已经生成了在体外切割单纯疱疹病毒 1 编码的 mRNA 并抑制病毒感染的人细胞中其表达的高度活性的核酶变体。在本章中,我们将人巨细胞病毒(HCMV)的 IE1 和 IE2 蛋白的 mRNA 的重叠区域用作靶底物。我们提供了详细的方案,并包括建立用于扩增和选择具有活性的 mRNA 切割核酶 P 核酶的程序的方法。体外扩增和选择系统代表了一种极好的方法,可用于工程高度活性的核酶 P 核酶,可用于基础研究和临床应用。